On November 4, 2024, NLS Pharmaceutics Ltd. entered into a merger agreement with Kadimastem Ltd., resulting in Kadimastem merging into a subsidiary of NLS, with Kadimastem shareholders expected to own 80% of the combined company; the deal includes asset disposals post-merger and a required cash threshold of $600,000 for NLS at closing.